PharMedica
Orally Dissolved Films (ODF) for sustained controlled release drug delivery
Company Overview
Snapshot
Founded in March 2008 by Yoram Rubin, PharMedica operates with 11–50 employees. The company has secured one disclosed funding round and holds one patent. In February 2024, PharMedica secured a grant from the Israel Innovation Authority.
Business overview
PharMedica is a biopharmaceutical company specializing in the development of a polymeric-based delivery platform. This platform enables the controlled and sustained release of drugs, nutraceuticals, and food additives. Utilizing a unique and proprietary polymeric matrix, the technology facilitates intraoral transmembrane delivery, directly targeting specific body parts to enhance the bioavailability and effectiveness of therapeutic active substances. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drug Delivery, serving patients and providers in the healthcare and life sciences industries.
Company Intelligence Q&A
- What is PharMedica's core technology?
- PharMedica develops a polymeric-based delivery platform designed for controlled and sustained release of various active substances, including drugs, nutraceuticals, and food additives, through an intraoral transmembrane delivery system.
- When was PharMedica founded?
- PharMedica was founded in March 2008.
- Who is the co-founder and CEO of PharMedica?
- Yoram Rubin is the Co-founder and CEO of PharMedica.
- What product does PharMedica currently offer?
- PharMedica offers iCling for dry mouth relief, which is one of its released products. This product leverages the company's polymeric-based delivery platform for intraoral transmembrane delivery.
- What was a recent significant development for PharMedica?
- In February 2024, PharMedica secured a grant from the Israel Innovation Authority for Proof of Concept (POC).